• Frizzled5: Cholesterol Sensing Links Lipid Metabolism to Wnt

  2026-07-30

  A recent study uncovers that Frizzled5 (Fzd5) uniquely binds cholesterol, linking aberrant cholesterol metabolism to Wnt/β-catenin signaling and tumor growth in pancreatic ductal adenocarcinoma (PDAC). This mechanism highlights Fzd5 as a cholesterol sensor, coupling lipid metabolism to morphogen pathways, and suggests new therapeutic avenues for Wnt-dependent cancers.

• NPC1/USP7/p53 Axis Drives Cholesterol and HCC Proliferation

  2026-07-30

  This study uncovers how the NPC1/USP7/p53 signaling axis orchestrates cholesterol metabolism and directly promotes hepatocellular carcinoma (HCC) cell proliferation. The findings reveal novel mechanistic links between lysosomal cholesterol transport, p53 destabilization, and tumor progression, highlighting potential therapeutic targets within this pathway.

• Applied Protocols with Recombinant Human IL-15 for Immune As

  2026-07-29

  Harnessing the precision and potency of Recombinant Human IL-15, researchers can drive robust T and NK cell responses and streamline immune modulation workflows. This article details actionable protocol enhancements, advanced troubleshooting, and the product’s unique fit for neuroimmune research, bridging insights from the latest oxytocin-signaling studies.

• GST-Mediated Resistance in Megalurothrips usitatus: Diethylm

  2026-07-29

  This study elucidates how glutathione S-transferase (GST) upregulation in Megalurothrips usitatus enhances resistance to the insecticide lambda-cyhalothrin by fortifying antioxidant defenses. Functional GST inhibition with diethyl maleate reveals the centrality of redox regulation in insecticide resistance, offering new molecular perspectives for resistance management and oxidative stress research.

• Epigenetic Suppression of Mcl-1 Sensitizes GBM to BCL-XL Inh

  2026-07-28

  This study demonstrates that epigenetic targeting of Mcl-1 using a super-enhancer blocker creates synthetic lethality when combined with BCL-XL/BCL-2 inhibition in glioblastoma models. The findings provide a mechanistic rationale for dual targeting of anti-apoptotic proteins to overcome apoptosis resistance in aggressive brain tumors.

• Digoxin as a Na+/K+ ATPase Pump Inhibitor: Advanced Research

  2026-07-28

  Digoxin empowers researchers to model cardiac contractility and study cell-specific antiviral responses with unmatched precision. Explore workflow enhancements, troubleshooting essentials, and key experimental parameters that leverage APExBIO’s high-purity Digoxin for both cardiovascular and viral infection research.

• Masitinib (AB1010): Technical Guidance for Targeted KIT Inhi

  2026-07-27

  Masitinib (AB1010) is a selective tyrosine kinase inhibitor tailored for researchers investigating KIT, PDGFRα, and PDGFRβ signaling, with particular relevance to cancer biology, mastocytosis, and inflammatory disease models. It is best suited for DMSO-based assays requiring precise kinase inhibition, and is not recommended for workflows that require aqueous or ethanol solubility or broad-spectrum kinase inhibition.

• Myriocin Restores Metabolic Homeostasis in dAGE-Induced Obes

  2026-07-27

  This study demonstrates that myriocin, a selective serine palmitoyltransferase inhibitor, reverses obesity and metabolic dysfunction in mice exposed to dietary advanced glycation end products by activating AMPK-PGC1α signaling and enhancing mitochondrial function. These findings establish sphingolipid inhibition as a promising avenue for addressing metabolic syndrome linked to dietary factors.

• Tropisetron Hydrochloride: Reliable 5-HT3 Antagonist for Lab

  2026-07-26

  This article addresses laboratory challenges in cell viability, proliferation, and transporter assays, using Tropisetron Hydrochloride (SKU B2258) as a validated, data-backed solution. We explore scenario-driven Q&A that leverage its receptor selectivity, solubility, and inhibitor potency, offering practical guidance aligned with the needs of biomedical researchers and bench scientists.

• Microlipophagy Drives Radioresistance in Small Cell Lung Can

  2026-07-25

  This study uncovers how microlipophagy-mediated lipid droplet remodeling promotes radioresistant phenotypes in small cell lung cancer (SCLC). By integrating autophagy inhibition and transcriptomic analysis, it reveals the metabolic adaptations underlying radiotherapy failure, highlighting microlipophagy as a potential therapeutic target.

• Bradykinin as an Endothelium-Dependent Vasodilator: Applied

  2026-07-24

  Bradykinin unlocks advanced experimental control over vascular permeability and inflammation, supporting high-precision cardiovascular and pain mechanism studies. This article delivers in-depth workflow guidance, troubleshooting tips, and protocol parameters for maximizing reproducibility with APExBIO’s Bradykinin research-grade peptide.

• Vorinostat in Translational Oncology: Mechanisms & Strategie

  2026-07-24

  This thought-leadership article unifies the mechanistic foundations of Vorinostat (suberoylanilide hydroxamic acid) as an HDAC inhibitor with actionable protocol guidance and new insights into apoptosis signaling. Drawing on recent discoveries in RNA Pol II-regulated cell death and benchmarking Vorinostat’s translational relevance, we offer strategic advice for researchers navigating the evolving landscape of epigenetic modulation and apoptosis assays in cancer biology.

• HyperScribe SP6 High Yield RNA Synthesis Kit: Precision for

  2026-07-23

  The HyperScribe SP6 High Yield RNA Synthesis Kit empowers cutting-edge RNA research through robust, high-yield synthesis—enabling advanced probe design, RNA vaccine studies, and immune pathway interrogation. Its exceptional yield, flexibility for RNA modification, and streamlined protocol make it an indispensable tool for researchers tackling complex virology and innate immunity questions.

• 2-D08: A Selective Inhibitor of Protein Sumoylation in Resea

  2026-07-23

  2-D08 (2’,3’,4’-trihydroxyflavone) is a potent, highly selective small molecule inhibitor of protein sumoylation, uniquely blocking SUMO transfer at the E2-substrate step. Its mechanism and solubility profile make it valuable for studying posttranslational modification in cancer research and beyond.

• GSK621: Precision AMPK Agonist for AML and Immunometabolic A

  2026-07-22

  GSK621 delivers potent, selective AMPK activation for acute myeloid leukemia and immunometabolic research, outperforming legacy agonists in both efficacy and substrate phosphorylation. This guide translates recent mechanistic insights into actionable workflows, protocol refinements, and troubleshooting strategies for reproducible metabolic pathway interrogation.

11705 records 1/781 page Next 12345 下5页 Last page